ArticleScientific reports2025
Astragaloside IV attenuates uremia-induced myocardial injury by inhibiting autophagy via ATF4.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCardiovascular diseases (CVDs) are one of the primary causes of mortality in patients with uremia. The therapeutic value of intravenous Astragaloside (AS-IV) in the treatment of CVDs has been widely recognized. However, whether AS-IV treats CVDs complicated by uremia remains unknown. This study aimed to determine the effects and potential mechanisms of AS-IV in the treatment of CVDs associated with uremia.
methodsThe 5/6 nephrectomized mouse model and uremic serum (US)-induced myocardial injury model of H9C2 cells were established in this study. Various techniques, including echocardiography, ELISA, TUNEL assay, flow cytometry, Western blotting, immunofluorescence, transmission electron microscopy, and qRT-PCR, were employed to investigate the effects of AS-IV on uremia-associated myocardial injury and determine its impact on autophagy and related signaling pathways. An ATF4 inhibitor and plasmid transfection techniques were used to modulate ATF4 expression and investigate the role of ATF4 in the protective effects of AS-IV on myocardial injury.
resultsAS-IV significantly improved cardiorenal function and attenuated uremia-associated cardiomyocyte apoptosis in 5/6 nephrectomized mice. Autophagy was significantly activated, and ATF4 expression was increased in 5/6 nephrectomized mice and uremic toxin-treated cardiomyocytes. AS-IV also significantly inhibited ATF4 expression and cardiomyocyte autophagy. Inhibition of ATF4 expression reduced cardiomyocyte apoptosis, while ATF4 overexpression significantly attenuated the cardioprotective effects of AS-IV. AS-IV significantly activated the PI3K pathway, while modulation of ATF4 expression affected AS-IV-mediated activation of the PI3K pathway.
conclusionsAS-IV ameliorated uremia-associated myocardial injury by suppressing ATF4 expression and regulating cardiomyocyte autophagy. The PI3K pathway may modulate autophagy after treatment with AS-IV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.